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Abstract
Cathepsins have been best characterized in tumorigenesis and cell death and implicated in liver
fibrosis; however, whether cathepsins directly regulate hepatic stellate cells (HSC) activation and
proliferation, hence modulating their fibrogenic potential is largely unknown. Here we show that
expression of cathepsin B (CtsB) and cathepsin D (CtsD) is negligible in quiescent HSC but parallels
the increase of α-SMA and TGF-β during in vitro mouse HSC activation. Both cathepsins are
necessary for HSC transdifferentiation into myofibroblasts, as their silencing or inhibition decreased
HSC proliferation and the expression of phenotypic markers of HSC activation, with similar results
observed with the human HSC cell line LX2. CtsB inhibition blunted AKT phosphorylation in
activated HSC in response to PDGF. Moreover, during in vivo liver fibrogenesis by CCl4
administration, CtsB expression increased in HSC but not in hepatocytes, and its inactivation
mitigated CCl4-induced inflammation, HSC activation and collagen deposition. Altogether, these
findings support a critical role for cathepsins in HSC activation, suggesting that the antagonism of
cathepsins in HSC may be of relevance for the treatment of liver fibrosis.
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Liver fibrosis represents the final common pathological outcome of many chronic liver insults,
and a major medical problem (1,2). Despite recent advances in the understanding of the
activation of hepatic stellate cells (HSC) and their role in liver fibrogenesis, relatively little is
known about the molecular mechanisms that regulate these processes.
As in other tissues, the fibrotic component of the liver’s wound-healing response is mediated
by myofibroblasts. In the injured liver, myofibroblasts are potentially derived from a number
of cellular sources, including activated HSC, which constitute a predominant reservoire for
myofibroblasts (1-4). HSC are responsible for extensive synthesis and deposition of
extracellular matrix (ECM) during liver fibrosis. Upon liver injury, HSC undergo a phenotypic
transformation from non-proliferating, retinoid storing cells, to a proliferating, matrix
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producing phenotype (1-6). HSC activation occurs in a two-step process, the initiation phase
characterized by loss of retinoids and upregulation of cytoskeletal protein expression such as
α -SMA and desmin, and the perpetuation phase where the ensuing myofibroblasts not only
produce almost all of the ECM but also a broad array of cytokines and chemokines that amplify
HSC activation via autocrine stimulation (1,6). Up to date, treatment for advanced liver fibrosis
and cirrhosis is inefficient, and the development of successful anti-fibrotic therapies is
imperative.
The cathepsins family comprises the catalytic serine (cathepsin G), aspartate (cathepsins D and
E) and cysteine (cathepsins B, C, H, F, K, L, O, S, V, and W) peptidases that exhibit endo-or
exopeptidase activities (7,8). Apart from their known role in protein turnover, recent data have
revealed that cathepsins can also regulate multiple processes including neovascularization of
endothelial progenitor cells (9), antigen presentation (10), cell growth and tissue homeostasis
(11-13). Moreover, cathepsins also have important functions outside lysosomes. For example,
execution of programmed cell death, degradation of ECM components, or induction of invasive
cell growth have been described when cathepsins are released into the cytosol or secreted in
the extracellular space (14-18). Consistent with these functions, and since ECM degradation
is a hallmark of tumorigenesis, aspartic protease cathepsin D (CtsD) and the cysteine cathepsin
B (CtsB) have been implicated in cancer progression, invasion and metastasis (7,14,19-21).
In addition, cathepsins have also been involved in liver injury and fibrogenesis. For instance,
cathepsin T and CtsD activation has been observed in experimental fibrogenesis (22) and
previous studies reported high levels of CtsB, D and L in serum of patients with cirrhosis and
hepatocellular carcinoma (23-25). Moreover, using two-dimensional polyacrylamide gel
electrophoresis, Kristensen et al. reported the upregulation of a number of proteins, including
CtsD, during the activation of rat HSC and liver fibrogenesis (26), whose expression correlated
with PDGF receptor β levels during HSC activation (27). Finally, Canbay et al described a
lysosomal pathway of hepatocellular apoptosis and liver injury following bile duct ligation
(BDL) in mice, in which CtsB played a key role, suggesting that CtsB-mediated hepatocellular
apoptosis contributed to inflammation and fibrogenesis (28). However, despite these
investigations whether cathepsins (CtsB or D) directly regulate HSC activation and
proliferation, or if modulation of cathepsins expression in HSC impacts on their fibrogenic
potential has not been specifically addressed.
Thus, our aim was to examine the contribution of CtsB and CtsD in the activation of mouse
HSC in vitro and in the development of fibrosis in vivo following CCl4 treatment. We show
that the levels of CtsB and CtsD are negligible in quiescent HSC but increase in parallel with
the upregulation α-SMA and TGF-β during HSC transdifferentiation into myofibroblasts.
Genetic silencing or pharmacological inhibition of cathepsins mitigate HSC activation and
hence progression of liver fibrogenesis.
EXPERIMENTAL PROCEDURES
Isolation and culture of hepatic stellate cells
C57BL/6 mice 8-12 week old were from Charles River. All animals received humane care
according to the criteria outlined in the “Guide for the Care and Use of Laboratory Animals”.
Hepatic stellate cells (HSC) were isolated from C57BL/6 mice by perfusion with collagenase-
pronase as described (29) with small modifications. HSC were separated from parenchymal
cells by 60×g centrifugation, collecting the supernatant for centrifugation at 450×g for 10min.
Pellet or non-parenchymal cells were resuspended and purified over a 17.2% Hystodenz
density gradient by centrifugation. The cloudy strip was collected and the HSC were cleaned
with Krebs-Henseleit buffer by centrifugation of 450×g for 10 minutes. Cells were cultured in
DMEM complemented with 10% FBS, and antibiotics at 37°C in a humidified atmosphere of
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95% air and 5% CO2. Culture purity was assessed by retinoid autofluorescence. Mouse HSC
were not passaged and were used from day-2 to day-10.
In vivo liver fibrogenesis
C57BL/6 mice were treated with carbon tetrachloride (CCl4) at a dose of 5μL (10% CCl4 in
corn oil)/g body weight, by intraperitoneal injection for 6 weeks twice a week. One hour before
treatment with CCl4, and during the last four weeks, mice received either CtsB inhibitor
(Ca074Me), or vehicle. Stock solutions of Ca074Me were made at a concentration of 10mg/
ml in dimethyl-sulfoxide. The stock was diluted 1:10 in saline and administered at 10mg/kg
body weight by intraperitoneal injection. Control animals received vehicle alone.
CtsB and CtsD activities
CtsB activity was assayed fluorimetrically with Z-Arg-Arg-7-amido-4-methylcoumarin
hydrochloride (60μmol/L) at pH 7.4 and 37 °C as previously described (30). Briefly, the assay
buffer employed contained 20mmol/L HEPES pH 7.4, 5% Sucrose, 0.1% 3-[(3-
Cholamidopropyl)dimethylammonio]-1-propanesulfonate, 2mmol/L EDTA, 5mmol/L
dithiothreitol, and 2mmol/L cysteine. The fluorimetric assay (λex: 360 nm; λem: 460 nm) was
performed in 96-well plate using 20 μg of protein per sample. Similarly, CtsD activity was
determined fluorimetrically (λex: 400 nm; λem: 505 nm) using the specific substrate N-Acetyl-
Arg-Gly-Phe-Phe-Pro-7-amido-4-trifluoromethylcoumarin (60μmol/L) at pH 7.4 and 37 °C.
The assay buffer contained 20mM HEPES pH 7.4, 5% Sucrose, 0.1% 3-[(3-Cholamidopropyl)
dimethylammonio]-1-propanesulfonate, 2mM EDTA, and 5mM dithiothreitol. Results were
expressed as cathepsin activity (slope of fluorescence emission after 40 min) per mg of protein.
In vitro siRNA transfection
To silence CtsB and CtsD expression, specific pre-designed siRNAs for mouse were used for
transfection using Lipofectamine LTX and PLUS following the manufacters’ instruction.
Briefly, 100nmol/L siRNA, 5μL of PLUS and 200μL of Optimem were mixed for 15min at
room temperature. 6μL of Lipofectamine LTX were added afterwards, transferring the mixture
to a 6-well plate after 25 min. In some cases, cells were transfected with both siRNA against
CtsB and CtsD, evaluating the expression of α-SMA, TGF-β and 2’-5’ oligoadenylate
synthetase 1 (OAS1). Cells were assayed usually 48h after siRNAs transfection.
[3H] Thymidine incorporation
Proliferation was estimated as the amount of [3H] thymidine incorporated into TCA-
precipitable material. HSC were cultured in a 6-well plate, and transfected at day 5. [3H]
thymidine (1μCi/mL) was added at 12, 24 and 48h after transfection and incubated for 24h.
The reaction was stopped by addition of 2ml cold TCA (5%). After two rinses with cold TCA
(5%), the radioactivity incorporated into TCA-insoluble material was recovered with 2.5mL
of 0.5 N NaOH and counted by liquid scintillation counting.
Statistical analyses
All images display representative data from at least 3 independent observations. Statistical
analyses were performed using Microsoft Excel software. The experiments were repeated at
least three times. The statistical significance of differences was performed using the unpaired,
non-parametric Student’s t test.
Reagent, Antibodies, and Methods
See Supporting Materials and Methods.
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RESULTS
CtsB and CtsD expression during mouse HSC activation
Since the culture of HSC is known to induce its transdifferentiation into a myofibroblast-like
phenotype, freshly mouse primary HSC were isolated to analyze CtsB and CtsD expression at
different time-points during culture. As shown in Fig. 1A the expression of CtsB and CtsD was
almost negligible in quiescent HSC (day 2); however, their levels markedly increased during
the time of culture with a maximum expression of both cathepsins seen at days 7-10; moreover,
its increase over time paralleled the appearance of α-SMA (Fig. 1A), an indicator of the
phenotypic transformation of HSC into myofibroblasts. The higher protein expression
observed in panel A was accompanied by increased functional activity of both cathepsins (Fig.
1B). More important, conditioned media from overnight cultures of 7 day-old HSC revealed
the presence of CtsB and CtsD in the extracellular media (Fig. 1C). This is consistent with the
study by Kristensen et al., which reported the presence of CtsD in the extracellular media from
activated rat HSC cultures (26). As illustrated in Fig. 1C, there is a molecular weight shift in
the extracellular media for both cathepsins compared to the form present in cellular lysates. In
the case of the secreted form of CtsB, the molecular weight is 25 kDa, derived from the
processing of the 30kDa intracellular active form (31). Unexpectedly, the molecular weight of
the secreted form of CtsD is approximately 28kDa, smaller than the intracellular 32kDa double-
chain of mature CtsD form, which has not been described previously to the best of our
knowledge. Moreover, both, CtsB and CtsD were localized in lysosomes, as shown by confocal
imaging of 7-day old HSC double-stained with a lysosomal marker, and anti-CtsB or anti-CtsD
antibodies (Fig. 1D). In addition, both cathepsins colocalized with each other in a punctate
pattern (Fig. 1E), and co-localized also with Rab5A and Rab7, early and late endosome markers
respectively, indicating that these enzymes follow the secretory pathway for its secretion to
the extracellular media (Fig. 1F).
CtsB and CtsD silencing downregulates mouse HSC proliferation and expression of
fibrogenic genes
We next examined the contribution of CtsB and CtsD on HSC activation following CtsB/CtsD
silencing via siRNAs. To this aim, 5-day old HSC were transfected with control, CtsB and/or
CtsD siRNA. The targeting of CtsB and CtsD by siRNAs reduced their protein levels by more
than 80% in both cell lysates and extracellular media (Fig. 2A). Silencing of either CtsB or
CtsD resulted in decreased cell proliferation (Fig. 2B), compared to HSC transfected with
control siRNA, with a more prominent effect observed for CtsD than CtsB. Blocking
simultaneously both cathepsins resulted in a synergic potentiation of the inhibitory effect on
proliferation (Fig. 2B). Moreover, downregulation of CtsB and/or CtsD also affected the levels
of phenotypic markers of HSC activation, such as α-SMA and TGF-β, as soon as 24h after
transfection, without affecting the interferon responsive gene 2’-5’-oligoadenylate synthetase
1 (OAS1) (32), indicating that siRNA transfection did not induce interferon response (Fig. 2C).
As a positive control of IFN-response we used LPS (1μg/ml, 24h) resulting in 6-7 fold increase
in OAS1 mRNA (not shown). In addition, we observed a dramatic loss of HSC migration,
examined by a wound-healing assay, in cells depleted of CtsB, but not of CtsD, indicating a
possible role of CtsB in the regulation of migration (Fig. 2D). We also examined the effect of
pharmacological inhibition of CtsB on HSC activation. Parallel to the effect observed after
silencing CtsB, its inhibition by Ca074Me, a potent and specific CtsB inhibitor (Fig. 2E)
(33), resulted in the downregulation of α-SMA and TGF-β mRNA both at level of mRNA and
protein (Fig. 2F).
Role of CtsB and CtsD in the human HSC cell line LX2
To examine the relevance of the preceding findings in human fibrogenesis, we next examined
the expression of CtsB and CtsD in LX2 cells, an immortalized human HSC cell line similar
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to human activated HSC (34). As seen, LX2 exhibited the presence of both CtsB and CtsD,
not only in the cellular lysates, but also in the extracellular media (Fig. 3A,B). In addition,
CtsB activity in LX2 cells was similar to that of 10-day old mouse HSC cultures (Fig. 3C).
Silencing of CtsB by siRNA transfection or its inhibition using Ca074Me downregulated α-
SMA mRNA and protein levels in LX2 cells (Fig. 3D,E), while this effect was not observed
upon CtsD silencing (not shown). However, reduction of CtsB and/or CtsD levels by siRNA
decreased cell proliferation, compared to control siRNA-transfected LX2 cells (Fig. 3F). In
contrast, CtsB inhibition by Ca074Me did not affect the expression of TGF-β mRNA in LX2
cells, nor their migration in a wound-healing assay (not shown), probably reflecting the fact
that TGF-β regulation and migration in fully activated LX2 cells may be different compared
to primary HSC, which models the initial phase of the transdifferentiation process (35,36).
Processing of CtsB and CtsD in mouse HSC
Cathepsins are synthesized as inactive precursors, which are then processed either
autocatalytically or by other enzymes to remove an N-terminal pro-peptide (37). For instance,
in mouse fibroblasts CtsD processing has been shown to require the function of cysteine
cathepsins, such as CtsB, to generate a mature CtsD form (38). Conversely, CtsD has been
shown to process CtsB precursor by the cleavage of the pro-cathepsin polypeptide (39). Thus,
we examined the effect of CtsB/CtsD inhibition or silencing on their reciprocal processing in
primary mouse HSC. As seen, CtsB inhibition by Ca074Me increased the CtsD precursor pro-
form (52 and 48 kDa), while decreasing the mature form (32 kDa) (Fig. 4A). Similarly, after
CtsD inhibition by Pepstatin A, an aspartyl protease inhibitor that blocks CtsD activity among
other proteases (40), we observed the downregulation of the CtsB mature form (30 kDa) (Fig.
4B). Comparable results were obtained after silencing CtsB (Fig. 4C) and CtsD by siRNAs
(Fig. 4D). Altogether, these results imply that CtsB and CtsD contribute to their mutual
proteolytic processing in primary mouse HSC.
CtsB modulates the PI3K/AKT pathway in activated mouse HSC
Platelet-derived growth factor-β receptor (PDGFβR) plays a key role in the transformation of
HSC into myofibroblasts and has been suggested as a putative target of cathepsins in activated
HSC (27,41). Thus, to investigate if CtsB and CtsD modulate the expression of PDGFβR, we
first examined their levels as a function of the activation of HSC from day-2 to day-10 in
culture, and the effect of CtsB or CtsD inhibition on PDGFβR degradation after platelet-derived
growth factor (PDGF) challenge. As observed (Fig. 5A), PDGFβR increased its expression
during the activation of mouse HSC, in parallel to the expression observed for CtsB and CtsD
(Fig. 1A). Pharmacological inhibition of CtsB or CtsD did not affect the degradation of
PDGFβR induced by its ligand PDGF (Fig. 5B). However, while PDGF elicited a rapid
phosphorylation of AKT, observed 15 min after PDGF challenge in activated HSC, this process
was markedly reduced in HSC cultures supplemented with the CtsB inhibitor Ca074Me (Fig.
5C). Moreover, CtsD inhibition by Pepstatin A did not affect the phosphorylation of AKT
induced by PDGF (Fig. 5C). Similar effects were observed after inhibition of the PI3K/AKT
pathway by LY294002, which blocked AKT phosphorylation by PDGF (Fig. 5D) and
decreased HSC proliferation following PDGF challenge (Fig. 5E). Overall, these findings
suggest that CtsB regulates the mitogenic potential of HSC via modulation of AKT in response
to PDGF.
CtsB overexpression in CCl4-treated mice
Since the preceding findings suggested a critical role of CtsB and CtsD in the activation of
mouse primary HSC, we next examined their expression during in vivo liver fibrogenesis
induced by CCl4, a well established model of liver injury. Immunohistochemical staining of
liver sections displayed an intense staining of CtsB only in CCl4-treated mice that co-localized
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with glial fibrillary acidic protein (GFAP), an HSC marker (42) (Fig. 6A). In contrast, CtsD
staining of liver sections exhibited a more diffuse pattern similar in control and CCl4 treated
livers that partially co-localized with GFAP (Fig. 6B). Since these findings suggested that the
increase expression of CtsB during liver fibrogenesis is restricted to HSC and because this
particular cathepsin has been involved in TNF, cholestasis-mediated hepatocellular injury and
free fatty acid-induced hepatic lipotoxicity in HepG2 cells (28,43,44), we examined the activity
of CtsB and CtsD in CCl4-treated liver in comparison with that of 2-day and 10-day old mouse
HSC cultures. While CtsD activity was similar in the liver of control or CCl4-treated mice, and
in 10-day old HSC cultures, the activity of CtsB was very low in mouse liver, regardless of
CCl4 treatment, compared to the activity observed in 10-day old HSC (Fig. 6C). Similar results
were observed when analyzing CtsB and CtsD protein levels (Fig. 6D), confirming the
immunohistochemical findings (Fig. 6A,B). Thus, these results indicate that CtsB and CtsD
are differentially expressed in HSC and hepatocytes during CCl4-induced liver fibrogenesis,
and that CtsB upregulation is limited to HSC in CCl4-treated mice.
CtsB inhibition mitigates CCl4-mediated liver fibrogenesis
Given the above findings, we next asked whether CtsB inhibition could be of relevance in
reversing liver fibrogenesis in vivo following CCl4 administration. In order to stimulate HSC
activation before inhibiting CtsB, CCl4 was administered twice a week for 2 weeks, followed
by CCl4 and Ca074Me administration for 4 additional weeks (Fig. 7A). CtsB inhibition by
itself did not alter any of the parameters studied in control animals (Fig. 7). CCl4 challenge for
6 weeks increased serum ALT compared to control or vehicle levels, which was not
significantly altered after CtsB inhibition by Ca074Me (Fig. 7B). H&E staining of liver sections
(Fig. 7C) displayed ECM accumulation and sinusoidal dilatation in CCl4-treated mice, which
were decreased after treatment with Ca074Me. These therapeutic effects were not due to
impaired metabolism of CCl4 in Ca074Me-treated animals since microsomal cytochrome P450
2E1 activity was comparable in both CCl4 treated groups irrespectively of the presence of the
inhibitor (not shown). However, CtsB inhibition in CCl4-treated mice resulted in a more
preserved architecture of liver parenchyma with less fibrosis. Moreover, as shown in Fig. 7D,
determination of the hydroxyproline content in the liver revealed a significant decrease in
collagen accumulation in CCl4-treated mice that received Ca074Me, compared to mice
challenged with CCl4 alone. This result was further confirmed by the increased detection of
collagen fibers by Sirius Red staining (Fig. 7E) in CCl4-treated animals compared to those
treated with CtsB inhibitor. In addition, CtsB inhibition in CCl4 treated animals decreased α-
SMA positive staining of liver sections, accompanied by almost negligible neutrophilic
infiltration as determined by myeloperoxidase staining (Fig. 7F). Thus, these findings indicate
that while the function of CtsB in CCl4-induced hepatocellular damage is negligible, CtsB
plays a critical role in in vivo liver fibrogenesis.
DISCUSSION
Cathepsins are lysosomal proteases that have been mainly involved and best characterized in
tumorigenesis and metastasis due to extensive ECM remodeling and in the regulation of cell
death pathways (18,21,45,46). Although cathepsins have been implicated in liver fibrogenesis
as well (22-25), their role in the regulation of HSC biology and their fibrogenic potential is
largely unknown. The present report provides evidence for a critical role of cathepsins,
particularly CtsB and CtsD, in HSC activation and proliferation, modulating their
transdifferentiation into myofibroblasts-like phenotype that ultimately controls liver
fibrogenesis.
We show that CtsB and CtsD expression increase during in vitro mouse HSC activation and
that this upregulation occurs largely in lysosomes, although a significant fraction is secreted
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in the extracellular media. The colocalization of cathepsins with markers of early and late
endosomes indicates that the release of lysosomal cathepsins follows the secretory pathway to
potentially modulate ECM components and plasma membrane HSC receptors.
Previous studies reported that secreted CtsB contributed to the degradation of PDGFβR (41),
suggesting that the inability of PDGF to induce HSC proliferation in quiescent HSC was due
to the degradation of PDGFβR. However, our findings portrait a different scenario according
to which CtsB would directly modulate HSC proliferation by a novel mechanism. Genetic and
pharmacological antagonism of CtsB prevents the proliferation of either activated murine HSC
cells or the immortalized human LX2 cells. However, rather than regulating the degradation
of PDGFβR in response to its ligand PDGF, we observed that the inhibition of CtsB impairs
the phosphorylation of AKT by PDGF. Thus, these findings suggest that CtsB positively
regulates the PI3K/AKT pathway in response to PDGF. The exact mechanism or intermediate
proteins responsible for the decreased activation of AKT observed in the absence of CtsB
activity in vitro after PDGF challenge is of utmost importance and merits further investigation.
In addition to preventing HSC proliferation, downregulation of CtsB and CtsD negatively
regulates the expression of phenotypic markers of HSC activation such as α-SMA and TGF-
β. These findings indicate that cysteine and aspartyl cathepsins directly modulate the early
transdifferentiation and perpetuation phase of HSC activation, critical steps for the regulation
of their fibrogenic potential and hence liver fibrogenesis. However, while we observed also a
decrease in TGF-β expression in primary mouse HSC, TGF-β mRNA levels did not change in
LX2 cells probably reflecting that these cells are more differentiated than 5-day old mouse
HSC, and that the regulation of TGF-β at this stage of differentiation may be different, as
suggested by others (35,36).
An important finding of this study is the description of active CtsB and CtsD in the extracellular
media of HSC, both in primary mouse HSC and in human LX2 cells. This observation is
significant since decreased pH may occur at local sites of tissue injury during inflammation,
favoring the activation of secreted cathepsins. In fact, secretion of cathepsins correlates
positively with invasiveness and metastatic properties of many tumor entities (7,17,31),
implying that CtsB facilitates invasion by degrading ECM components or by activating other
matrix-degrading proteases like the urokinase-type plasminogen activator (47).
Given the role of CtsB/CtsD in orchestrating the proliferating and fibrogenic potential of
activated HSC, we next addressed their impact on liver fibrogenesis in vivo. Extending the
previous observations of Canbay et al in the BDL model of liver fibrogenesis (28), we analyzed
the role of CtsB in CCl4-mediated liver fibrosis. In agreement, we observed that
pharmacological inhibition of CtsB prevented the increase in α-SMA upregulation, collagen
synthesis and neutrophil infiltration induced by CCl4. In contrast, while CtsB inhibition in
BDL-induced liver fibrosis reduced hepatocellular damage which, was shown to contribute to
HSC activation (28), we observed that CtsB inhibition did not ameliorate the liver damage
caused by CCl4, probably reflecting that the involvement of CtsB in hepatocellular damage
may well be stimuli dependent (28,43,44). Besides, the upregulation of CtsB during CCl4
administration was confined to HSC, with almost undetectable levels found in hepatocytes, as
evidenced by its colocalization with GFAP, and by biochemical analyses of CtsB activity. In
this regard and given the nature of GFAP staining, we cannot rule out the participation of CtsB
in other myofibroblastic populations in the liver (42,48). Similarly, and given the complex
post-translational regulation of cathepsins (37,38), we cannot discard the involvement of other
related family members in the activation of HSC and modulation of their fibrogenic potential.
Finally, a relevant aspect of our findings is that the CtsB inhibitor, Ca074Me, administered 2
weeks after CCl4 treatment to allow the initial activation of HSC, was able to reduce fibrosis
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progression. Although further research in this area is needed, our results position HSC
cathepsins as potential therapeutic targets for the treatment of liver fibrosis.
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glial fibrillary acidic protein
HSC  
hepatic stellate cells
PDGF  
Platelet-derived growth factor
PDGFβR  
PDGF-β receptor
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Figure 1.
Mouse HSC express CtsB and CtsD. (A) Time-course of CtsB, CtsD, and α-SMA protein
expression by western blot. (B) CtsB and CtsD activity. (C) CtsB and CtsD present in the
extracellular media (EM) differ from the intracellular form (CL). Western blot displaying two
representative experiments (Experiment #1: lane 1-2; experiment #2: lane 3-4). (D-F) Confocal
imaging of 7 day-old HSC displaying CtsB, CtsD, with a lysosomal marker (LAMP2b) (D),
among themselves (E), and with early (Rab5A) or late (Rab11) endosome markers (F). Data
are mean±SD, n=4 and *p≤ 0.05 vs. day 2 HSC. Scale bar 10μm (D-F).
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Figure 2.
CtsB or CtsD silencing weakens HSC activation. CtsB and CtsD expression (A), proliferation
(B), OAS1, α-SMA and TGB-β mRNA expression (C), and migration (D) after CtsB and/or
CtsD silencing for 48h in 5 day-old HSC. CtsB activity (E) and α-SMA protein, and α-SMA
and TGB-β mRNA expression (F) after Ca074Me challenge (10μmol/L) for 48h in 5-day old
HSC. Data are mean±SD, in B and C, n=3 and *p≤ 0.05 vs. siRNA Ctrl transfected HSC; in E
and F, n=3 and *p<0.001 vs. vehicle treated HSC.
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Figure 3.
CtsB and CtsD in LX2 cells. CtsB and CtsD expression by Western blot in LX2 cells (A), and
its presence in the extracellular media (B). In B, the Western blot displays two representative
experiments (Experiment #1: lane 1-2; experiment #2: lane 3-4). CtsB activity in LX2 cells
and 10-day HSC (C). α-SMA protein (D), and mRNA expression (E) after CtsB silencing for
48h. (F) Proliferation after CtsB and/or CtsD silencing. Data are mean±SD, in D, n=3 and *p≤
0.001 vs. Ctrl HSC; in E, n=3 and *p≤0.05 vs. siRNA Ctrl transfected LX2 cells.
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Figure 4.
CtsB and CtsD processing in HSC. Inhibition of CtsB in 5 day-old HSC with Ca074Me
(10μmol/L) for 24h affects CtsD processing (A). Similarly, CtsD inhibition, with Pepstatin A
(10μg/ml) for 24h, resulted in less CtsB active form (B). Parallel results were observed after
CtsB or CtsD silencing (C,D). Data are mean±SD, *p≤ 0.05 vs. untreated HSC.
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Figure 5.
PI3K/AKT activation after CtsB inhibition in vitro. (A) PDGFβR levels during mouse HSC
activation from day-2 to day-10. (B) Effect of CtsB (Ca074Me 10μmol/L, 24h) or CtsD
(Pepstatin A 10μg/ml, 24h) inhibition on PDGFβR degradation after challenge with PDGF (60
min), and on AKT phosphorylation after PDGF challenge (15 min) (C). (D,E) Effect of the
PI3-kinase inhibitor LY294002 (10μmol/L, 60 min preincubation) on the phosphorylation of
AKT by PDGF (15 min) (D), and on the proliferation for 24h (E). Data are mean±SD, in D,
n=3 and *p≤ 0.05 vs. control HSC; # p≤ 0.01 vs. PDGF-treated HSC.
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Figure 6.
CtsB and CtsD expression in experimental fibrosis in vivo. (A,B) Immunofluorescence imaging
of CtsB (A) or CtsD (B) and GFAP in control and 4-week treated CCl4 liver sections. The lower
panel of A and B displays a magnification of the upper-right section indicated by the dashed
line (C,D) CtsB, and CtsD activity (C) or protein expression (D) in day-2, day-10 HSC, and
control and 4-weeks CCl4 treated livers. Data are mean±SD, in C, n=3 and *p≤ 0.01 vs. control
liver. Scale bars 50μm in all panels, except in the lower panels (25μm).
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Figure 7.
CtsB inhibition in CCl4-treated mice. (A) Experimental setup of CCl4 and Ca074Me
administration to mice. (B-F) 6-week after initial CCl4 challenge we determined serum ALT
levels (B), H&E staining of liver sections (C), hydroxyproline levels in liver homogenate (D),
Sirius Red staining of liver sections(E), and immunostaining with α-SMA and myeloperoxidase
(MPO) to evaluate neutrophilic infiltration (F) in the different groups. Data are mean±SEM,
in B, n=5 animals per group and *p≤ 0.01 vs. corn oil-treated mice; in D, n=5 animals per
group and *p≤ 0.01 vs. corn oil-treated mice, and #p≤ 0.05 vs. CCl4+vehicle-treated mice.
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